Kornimate/medical-research-clean huggingface dataset:
screening for abdominal aortic aneurysms in the general practice by ultraportable ultrasound

Conditions: Abdominal Aortic Aneurysm

Summary: abdominal aortic aneurysm (aaa) is a localized dilatation of a segment of the aorta artery in its abdominal portion. it affects 1.7% of men aged 65 years and older. in the high-risk population (male smokers aged 65-75 years), its prevalence is estimated to be between 2.8 and 9%. mortality of ruptured aaas is high (80% of deaths before hospitalization or perioperatively), whereas mortality of scheduled procedures for unruptured aaas is less than 5%. aaa screening has been shown to significantly reduce the specific mortality rate in the medium and long term. the french national authority for health (has) recommends targeted screening for aaa by ultrasound at the radiologist. the target population is male smokers or former smokers aged 65 to 75 years, as well as all persons aged 50 to 75 years with a family history of aaa. despite recommendations, the rate of access to targeted screening appears low. ultrasound screening for aaa is a rapid, noninvasive, and reproducible test. it relies primarily on the measurement of the maximum diameter of the abdominal aorta in cross-section. it has been demonstrated that the learning of the ultrasound screening procedure for aaa is very fast and that the performance of non-radiologists trained in this procedure alone is similar to that of radiologists. in addition, new ultra-portable ultrasound devices, inexpensive and with validated performances have appeared on the market in the last few years, making it possible to equip general practitioners (gps). we propose a simplified care pathway for aaa screening, by equipping gps with an ultra-portable ultrasound scanner and by training them to perform the screening procedure, which will be performed in the office or at the patient's home, during a usual consultation of general medicine. our hypothesis is that this new organization will allow better access to screening for the target population, at a lower cost, compared to the current screening method recommended by the has (referral of the patient to the radiologist).


Eligibility criteria:
inclusion criteria: * male * in the absence of a family history of aaa: patient aged 65 to 75 years, chronic current or past smoker, active smoker (defined as having smoked at least one cigarette per day) or former smoker (defined as having quit smoking less than 20 years ago, regardless of the number of cigarettes smoked). * if there is a family history of aaa: patient between 50 and 75 years of age * express consent to participate in the study * affiliated or beneficiary of a social security plan exclusion criteria: * patient with a legal protection measure * patient with previous aaa screening less than 5 years old * patient unable to understand the study / give informed consent (cognitive impairment, communication impairment)
coronary collateralization in type 2 diabetic patients with chronic total occlusion

Conditions: Chronic Total Occlusion of Coronary Artery; Diabetes Mellitus, Type 2

Summary: a severe coronary artery obstruction is a prerequisite for spontaneous collateral recruitment. the formation of coronary collateral circulation(ccc) is significantly impaired in type 2 diabetic patients with chronic total occlusion (cto) compared with non-diabetic patients with cto. this retrospective cohort enrolls consecutive t2dm patients who had at least one lesion with coronary angiographic total occlusion.

coronary collateralization in type 2 diabetic patients with chronic total occlusion (collect) study is a single center, retrospective cohort study to investigate potential factors associated with the development of coronary collateral circulation in diabetic patients. investigators will consecutively enroll t2dm patients who had at least one lesion with coronary angiographic total occlusion. the development of coronary collateral circulation will be graded according to the rentrop method and patients will be divided into poor ccc (grade 0 or 1) or good (grade 2 or 3) ccc groups according to their rentrop grades. baseline clinical and laboratory characteristics at hospital admission will be recorded to analyze potential factors associated with the development of coronary collateral circulation in t2dm patients with cto. later, their cardiac function will be evaluated by echocardiography at one year follow-up.

Eligibility criteria:
inclusion criteria: * age 18-90 years * type 2 diabetes diagnosed by one of the following criteria: hba1c \>/= 6.5% fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during ogtt \>/= 11.1 mmol/l already receiving glucose-lowering agents. * at least one lesion with angiographic total occlusion exclusion criteria: * egfr\<15ml/(min·1.73m2) * chronic heart failure with nyha grade ≥3 * had a history of coronary artery bypass grafting * had received a percutaneous coronary intervention within the prior 3 months * malignant tumor or immune system disorders * pulmonary heart disease

Keywords: atherosclerosis diabetes mellitus, type 2 chronic total occlusion of coronary artery coronary artery disease
femtosecond laser-assisted astigmatism treatment

Conditions: Age Related Cataracts; Astigmatism

Summary: the investigational device is an approved femtosecond laser (fsl) device with an integrated imaging system to perform certain steps of the cataract procedure including arcuate incisions (ai) correcting astigmatism, also referred to as arcuate keratotomy (ak). the fsl will perform anterior capsulotomy and lens fragmentation in individuals suffering from age-related cataract with need of cataract surgery and additionally perform arcuate keratotomy in individuals with more than 1.0 diopter (dpt) of astigmatism. cataract surgery will be performed in subjects who have signed an informed consent form. postoperative examinations will be implemented in accordance with the approved investigational plan on subjects and includes: postoperative refraction, visual acuity, slitlamp examination, and corneal topography


Eligibility criteria:
inclusion criteria: * age-related cataract necessitating lens extraction and posterior iol implantation * regular corneal astigmatism between 1.0 and 2.5 dpt * age 40 and older (females of childbearing age will be interviewed if pregnancy is possible) exclusion criteria: * corneal abnormality * preceding ocular surgery or trauma * uncontrolled glaucoma * proliferative diabetic retinopathy * iris neovascularization * history of uveitis/iritis * microphthalmus * recurrent intraocular inflammation of unknown etiology * blind fellow eye * uncontrolled systemic or ocular disease

Keywords: laser cataract surgery arcuate keratotomy
xavier electromyographic wheelchair control for limited mobility patients

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to assess the functional mobility and self-reported satisfaction with the xavier electromyography hands-free wheelchair control system in comparison with a standard joystick.


Eligibility criteria:
inclusion criteria: * als diagnosis by revised el escorial criteria (definite, probable or probable laboratory supported) * age 18-89 * limited mobility with use of motorized wheelchair at screening-time * impairment of hand function limiting the use of a standard joystick control * caregiver willing to assist with transfers into wheelchair and application of controllers * ability to attend study visits with a motorized wheelchair * ability to communicate and answer patient reported outcome measure questions exclusion criteria: * cognitive impairment prohibiting safe independent mobility as defined by an als-cognitive behavioral screen (als-cbs) score of \<10 or the opinion of the investigator * a sensory impairment prohibiting safe independent mobility in the opinion of the investigator * allergy to adhesives or electrode gels (required for emg electrodes) * skin breakdown over the temporalis muscle that would predispose to further breakdown and/or infection with electrodes * severe loss of facial muscle functionality or control that would preclude emg electrode efficacy * subjects who do not have the capacity to consent
stem cell educator therapy in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: type 2 diabetes is the most common form of diabetes. the prevalence of diabetes has been markedly increased in recent years. more and more children and young adults develop this devastating disease. despite of multiple factors (e.g., food, environmental, and genetic factors) contributing to the developing of diabetes, increasing evidence demonstrated that chronic inflammation and/or atuoimmunity are common issues and play key roles in the pathogenesis of type 2 diabetes, leading to the insulin resistance and the shortage of insulin-producing islet beta cells. thus, anti-inflammation is becoming a novel approach for the treatment of type 2 diabetes. evidence that multipotent stem cells derived from human cord blood (cb-scs) can control inflammation and autoimmune responses by altering regulatory t cells (tregs) and human islet beta cell-specific t cell clone in type 1 diabetes offers promise for a new approach to treat type 2 diabetes. here, the investigators develop a novel stem cell educator therapy by using cb-sc and explore the therapeutic effectiveness of stem cell educator therapy in t2d patients.


Eligibility criteria:
inclusion criteria: * patients were screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards of american diabetes association 2010. other key inclusion criteria were presence of at least one autoantibody to the pancreatic islet β cells for the autoimmune-related type 2 diabetes. exclusion criteria: * exclusion criteria were any clinically significant diseases in liver, kidney, and heart. additional exclusion criteria were no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.

Keywords: cord blood stem cells inflammation type 2 diabetes stem cell educator autoimmunity immune modulation
suicide prevention by lithium - the lithium intervention study

Conditions: Suicide; Depressive Disorders

Summary: the purpose of this study is to examine the proposed suicide preventive effects of lithium in a randomized controlled trial within a group of individuals with depressive disorders. the hypothesis being tested is that lithium treatment will significantly reduce the risk for another suicide attempt.

several studies have shown that there is a significantly increased risk of suicide related mortality in patients with a positive history of suicide attempts. this study is the first prospective, randomized, double-blind, placebo controlled multi-center trial focussing on the proposed suicide preventive effects of lithium in patients with suicidal behavior but not suffering from bipolar disorder or recurrent major depressive disorder. patients with a recent history of a suicide attempt are treated with lithium or placebo during a 12 month-period. the hypothesis is that lithium treatment will lead to a 50 % reduction of suicidal behavior.

Eligibility criteria:
inclusion criteria: * suicide attempt within 3 months prior to the first drug administration * occurrence of suicide attempt within the context of an affective spectrum disorder * minimum age of 18 years * ability to complete screening and baseline assessment * ability to understand and provide informed consent exclusion criteria: * diagnosis of schizophrenia, borderline personality disorder, substance related disorders * indication for long-term lithium treatment * thyroid disease * pregnancy and lactation

Keywords: suicide prevention lithium suicidality
latanoprost plus nb-uvb versus each alone in non-segmental vitiligo: clinical and laboratory evaluation

Conditions: Non-segmental Vitiligo

Summary: the aim of the study is to evaluate the efficacy of different lines of therapies on the tweak serum level in patients with non-segmental vitiligo.

the study is to evaluate the efficacy of nb-uvb, latanoprost, and combination of them on the tweak serum level in patients with non-segmental vitiligo.

Eligibility criteria:
inclusion criteria: * patients with non-segmental vitiligo of any age and gender. exclusion criteria: * history of vitiligo treatment with topical, systemic or biological agents prior to the study for at least 3 weeks. * pregnancy and lactation. * infections * patients with other autoimmune diseases. * patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies.
a study on the safety and effectiveness of adefovir dipivoxil in combination with anti-hiv therapy (haart) in hiv-positive patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give an experimental anti-hiv drug, adefovir dipivoxil (adv), in combination with other anti-hiv drugs (haart) to patients who have a viral load (level of hiv in the blood) between 50 and 400 copies/ml.

patients are randomized to 1 of 2 arms in a 2:1 ratio. approximately 260 patients receive adv and approximately 130 patients receive placebo. patients receive adv or placebo in addition to l-carnitine and their current stable haart regimen. each patient receives blinded study medication for 48 weeks and is evaluated at weeks 16, 24, and 48. patients who reach the primary endpoint of virologic failure prior to week 48 may continue blinded study medication or receive open-label adv at the investigator's discretion. in both cases, patients continue their study visits as per the original visit schedule. virologic failure is defined as 2 consecutive hiv-1 rna measurements, after baseline, above 400 copies/ml (measured by the roche amplicor hiv-1 monitor ultrasensitive assay) drawn at least 14 days apart. all patients who complete study visits without treatment-limiting adv toxicity may continue open-label adv in the maintenance phase at the discretion of the principal investigator.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * have been on a stable haart regimen consisting of at least 3 antiretroviral drugs for at least 16 weeks prior to study entry. * have a cd4 count of 50 cells/mm3 or more. * have a viral load greater than 50 and less than or equal to 400 copies/ml within 14 days prior to study entry. * have had at least 1 additional viral load in the past that was less than or equal to 400 copies/ml while on your current stable haart regimen.

Keywords: hiv-1 rna, viral vx 478 reverse transcriptase inhibitors anti-hiv agents viral load
the study of sleep disordered breathing in patients with interstitial lung diseases

Conditions: Obstructive Sleep Apnea-hypopnea

Summary: this was a cross-sectional observational study to evaluate the prevalence and predictive factors of sdb in ild and to analyze the relationship between polysomnography (psg) findings, pulmonary function, disease severity, parenchymal involvement, and sleep questionnaires ess and sbq. this study included 69 patients who were diagnosed with diffuse parenchymal lung diseases by high-resolution computed tomography (hrct) chest. all patients were subjected to clinical examination, hrct, spirometry, full-night polysomnography, and echocardiography.


Eligibility criteria:
inclusion criteria: * both sexes of clinically stable ild patients older than 18 who met the ats/ers criteria for an ild diagnosis were included in the study. exclusion criteria: * patients who have any anatomic upper airway obstructions such as significant nasal septal deviation, nasal polyps, conchae hypertrophy or tonsillar hypertrophy. * patients with neurological diseases or severe psychiatric disorders. * patients who have history of administration of any drug that has a major effect on sleep e.g. benzodiazepine, narcotic drugs ....etc. * patients with any chronic pulmonary disease except ild. * total sleep time less than 4 hours on psg.
impact of harvest lentil vegetable blend and nutrition education on turkana children's health outcomes

Conditions: Malnutrition, Child

Summary: the goal of this study was to test the effect of an intervention that integrated supplemental feeding program for children aged 6-59 months with a caregiver intensive nutrition education intervention on the health outcomes of turkan children aged 6-59 months. the purpose of this study was fivefold: (i) to assess child nutrition status, food security status, child feeding practices, water, hygiene and sanitation (wash) practices, and the associated factors in turkana county, kenya. (ii) to assess the nutrition knowledge, attitudes, subjective norms, perceived behavioral control, and intentions towards recommended child feeding practices among turkana caregivers of children aged 6-59 months. (iii) to assess the effect of a theory-based nutrition education intervention on nutrition knowledge, attitudes, subjective norms, perceived behavioral control, and intentions towards recommended child feeding practices among turkana caregivers of children aged 6-59 months, (iv) to evaluate the effect of a theory-based nutrition education intervention on child feeding practices and wash practices among turkana caregivers of children aged 6-59 months, (v) and to assess the effect of consuming harvest lentil vegetable blend combined with nutrition education intervention on the nutritional status of turkana children aged 6 -59 months. in this quasi-experimental study, children in the intervention group received a daily meal of harvest lentil vegetable blend (6 days/week) for eight weeks and their caregivers' received sessions of nutrition education on infant and young child feeding practices and wash practices. the participants in the control group were only given one bag of supplemental food on the days of data collection to compensate for their time


Eligibility criteria:
inclusion criteria: * children between 6-59 months * no known allergy reactions to rice, lentils, carrots and onions * being a permanent resident of nayada and sopel villages * willingness to participate in the study

Keywords: complementary feeding wash practices child undernutrition nutrition education harvest lentil vegetable blend supplemental feeding
retinol-binding protein 4 (rbp4) metabolizm in type 2 diabetes progression and associated cardiovascular complications

Conditions: Diabetes Mellitus, Type 2

Summary: retinol-binding protein 4 (rbp4) may affects obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and cardiovascular disease. this study aims to examine the involvement of rbp4 in patients with diagnosed diabetes, diabetic cardiovascular disease, pre-diabetes (pre-dm) and healthy controls during the progression of t2dm, and to evaluate the ability of rbp4 to predict cases of diabetes with an elevated risk of cardiovascular complications . along with animal experiment.

a total of 500 chinese patients admitted to the first affliated hospital of xi'an jiaotong university (xi'an, china) between march 2020 and march 2022 were recruited to investigate the rbp4 profles. peripheral blood samples are drawn at the initial medical examination, in the morning after a fast of at least 8 h, and immediately stored at -80˚c until the sphingolipid measurements were performed. blood pressure, wc, hip circumference (hc), body weight and body height were measured by a trained physician. the participants enrolled in the study provided written informed consent.

Eligibility criteria:
inclusion criteria: t2dm: * fasting plasma glucose (fpg)≥7.0 mmol/l; * 2 h plasma glucose (2hpg) ≥11.1 mmol/l; * glycated hemoglobin (hba1c) level ≥6.5%; * random plasma glucose ≥11.1 mmol/l plus symptoms of hyperglycemia; * t2dm diagnosed previously. pre-dm was defned as follows: * fpg ≥5.6-6.9 mmol/l * 2hpg 7.8-11.0 mmol/l * hba1c 5.7-6.4%. exclusion criteria: * type 1 diabetes * liver or kidney disorders.
ebv specific cytokine secreting tcr-t cells in the treatment of ebv-positive metastatic/refractory nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: epstein-barr virus (ebv) infections is known to be a high-risk factor to induce cervical cancers. to date, ebv-related nasopharyngeal carcinoma (npc) is still a major concern in east asia, especially in china. concurrent therapies for npc have limited response rate and high chance of relapse. however, ebv-induced cancers provided an ideal target for t cell-based immunotherapy due to the non-self origins. engineered t cells bearing a tcr (tcr-t) that can specifically recognize the presented ebv-epitope become a viable approach to treat this type of cancer. though engineered t therapies have been well-recognized in hematological cancers, solid cancer treatment has been a major hurdle due to the immune-suppressive tumor microenvironment. cytokine seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (nk cells) and adaptive immunities. therefore, tcr-t cells armed with a cytokine -secretion element could further enhance the efficacy of tcr-t in solid cancers.


Eligibility criteria:
inclusion criteria: * expected to live longer than 12 weeks * ps 0-2 * pathology confirmed as ebv positive npc, either metastatic or recurrent disease * creatinine \<2.5mg/dl * alt/ast is lower than three times uln. * no contraindications of leukocyte collection * before entering the trial, women must adopt a reliable method of contraception until 30 days after infusion. * understand this trial and have signed an informed consent exclusion criteria: * patients with symptomatic brain metastasis * with other uncontrolled malignant tumors. * hepatitis b or hepatitis c activity period, hiv infected patients * any other uncontrolled disease that interferes with the trial * patients with severe heart and cerebrovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis and cerebral hemorrhage * untreated hypertension or hypertensive patients * a person with a history of mental illness that is difficult to control * researchers do not consider it appropriate to participate in this trial * patients who have been using immunosuppressive agents for a long time after organ transplants, except for recent or current inhaled corticosteroids * subjects who have been pregnant or nursing, or who plan for pregnancy within 2 months of treatment or after the end of treatment * an illness affects a person who signs a written consent or complies with a study procedure, or who is unwilling or unable to comply with the research requirements
the discrepancy in radiologists' practice of intravenous contrast imaging studies among chronic kidney disease patients

Conditions: Chronic Kidney Diseases; Chronic Kidney Disease 5D

Summary: * there is a discrepancy between protocols used for intravenous imaging for chronic kidney disease including hemodialysis patients among different hospitals and even, among radiologists same selves. * this questionnaire based study aims to quantify that discrepancy and describe the variables associated with the discrepancy.

* there is a discrepancy between protocols used for intravenous imaging for chronic kidney disease including hemodialysis patients among different hospitals and even, among radiologists same selves. * this questionnaire-based study aims to quantify that discrepancy and describe the variables associated with the discrepancy.

Eligibility criteria:
inclusion criteria: * practicing radiologist exclusion criteria: * retired radiologist

Keywords: chronic kidney disease hemodialysis intrevenous contrast